Metagenomi Therapeutics, Inc.MGX
Price (close)
$1.15
Market cap
$43.4M
P/E
—
Revenue (TTM)
$25.2M
Net income
-$93.5M
Dividend yield
—
1-year total return
-50.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Metagenomi Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | $44.8M | $52.3M | $25.2M |
| Net income | — | -$68.3M | -$78.1M | -$87.9M |
| Free cash flow | — | -$101.2M | -$112.2M | -$89.5M |
More on MGX.
- Metagenomi Therapeutics, Inc. summary
- Metagenomi Therapeutics, Inc. financial statements
- Metagenomi Therapeutics, Inc. key metrics
- Metagenomi Therapeutics, Inc. health scores and style box
- Metagenomi Therapeutics, Inc. earnings
- Metagenomi Therapeutics, Inc. dividends
- Metagenomi Therapeutics, Inc. valuation
- Metagenomi Therapeutics, Inc. ownership and insiders
- Metagenomi Therapeutics, Inc. peers
Figures from Metagenomi Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.